{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:46:13Z","timestamp":1780512373724,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11060-018-2922-5","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T15:19:38Z","timestamp":1528471178000},"page":"749-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2"],"prefix":"10.1007","volume":"139","author":[{"given":"Diana S.","family":"Osorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Stanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias A.","family":"Karajannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"2922_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DGR Evans","year":"2009","unstructured":"Evans DGR (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16. \n                    https:\/\/doi.org\/10.1186\/1750-1172-4-16","journal-title":"Orphanet J Rare Dis"},{"key":"2922_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF00177474","volume":"27","author":"BS Chozick","year":"1996","unstructured":"Chozick BS, Benzil DL, Stopa EG, Pezzullo JC, Knuckey NW, Epstein MH, Finkelstein SD, Finch PW (1996) Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J Neuro-Oncol 27:117\u2013126","journal-title":"J Neuro-Oncol"},{"key":"2922_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3171\/jns.1997.87.2.0315","volume":"87","author":"RS Carroll","year":"1997","unstructured":"Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, Guha A (1997) Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87:315\u2013323. \n                    https:\/\/doi.org\/10.3171\/jns.1997.87.2.0315","journal-title":"J Neurosurg"},{"key":"2922_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","volume":"108","author":"U Andersson","year":"2004","unstructured":"Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108:135\u2013142. \n                    https:\/\/doi.org\/10.1007\/s00401-004-0875-6","journal-title":"Acta Neuropathol"},{"key":"2922_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/01.coc.0000128724.63600.c7","volume":"27","author":"A Potti","year":"2004","unstructured":"Potti A, Panwalkar A, Langness E, Sholes K, Tendulkar K, Chittajalu S, Koch M (2004) Role of her-2\/neu overexpression and clinical features at presentation as predictive factors in meningiomas. Am J Clin Oncol 27:452\u2013456","journal-title":"Am J Clin Oncol"},{"key":"2922_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.humpath.2005.12.020","volume":"37","author":"D Loussouarn","year":"2006","unstructured":"Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF (2006) Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 37:415\u2013421. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2005.12.020","journal-title":"Hum Pathol"},{"key":"2922_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/07357900802709175","volume":"27","author":"I Laurendeau","year":"2009","unstructured":"Laurendeau I, Ferrer M, Garrido D, D\u2019Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I (2009) Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest 27:691\u2013698. \n                    https:\/\/doi.org\/10.1080\/07357900802709175","journal-title":"Cancer Invest"},{"key":"2922_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1748-717X-5-46","volume":"5","author":"AG Wernicke","year":"2010","unstructured":"Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L (2010) Assessment of epidermal growth factor receptor (EGFR) expression in human meningioma. Radiat Oncol 5:46. \n                    https:\/\/doi.org\/10.1186\/1748-717X-5-46","journal-title":"Radiat Oncol"},{"key":"2922_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.prp.2012.01.009","volume":"208","author":"P Mahzouni","year":"2012","unstructured":"Mahzouni P, Movahedipour M (2012) An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade. Pathol Res Pract 208:221\u2013224. \n                    https:\/\/doi.org\/10.1016\/j.prp.2012.01.009","journal-title":"Pathol Res Pract"},{"key":"2922_CR10","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3892\/mmr.2015.3805","volume":"12","author":"W Wang","year":"2015","unstructured":"Wang W, Tu Y, Wang S, Xu S, Xu L, Xiong Y, Mei J, Wang C (2015) Role of HER-2 activity in the regulation of malignant meningioma cell proliferation and motility. Mol Med Rep 12:3575\u20133582. \n                    https:\/\/doi.org\/10.3892\/mmr.2015.3805","journal-title":"Mol Med Rep"},{"key":"2922_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF00225206","volume":"95","author":"L Papi","year":"1995","unstructured":"Papi L, De Vitis LR, Vitelli F, Ammannati F, Mennonna P, Montali E, Bigozzi U (1995) Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 95:347\u2013351","journal-title":"Hum Genet"},{"key":"2922_CR12","first-page":"827","volume":"146","author":"R Wellenreuther","year":"1995","unstructured":"Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, von Deimling A (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827\u2013832","journal-title":"Am J Pathol"},{"key":"2922_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/BF02281874","volume":"97","author":"LR De Vitis","year":"1996","unstructured":"De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, Montali E, Papi L (1996) Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet 97:632\u2013637","journal-title":"Hum Genet"},{"key":"2922_CR14","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/sj.onc.1202531","volume":"18","author":"PE Leone","year":"1999","unstructured":"Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestana A, Rey JA (1999) NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231\u20132239. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1202531","journal-title":"Oncogene"},{"key":"2922_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.909","volume":"194","author":"J Kros","year":"2001","unstructured":"Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E (2001) NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367\u2013372. \n                    https:\/\/doi.org\/10.1002\/path.909","journal-title":"J Pathol"},{"key":"2922_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/gcc.20141","volume":"42","author":"J Lomas","year":"2005","unstructured":"Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, Aminoso C, de Campos JM, Isla A, Vaquero J, Rey JA (2005) Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42:314\u2013319. \n                    https:\/\/doi.org\/10.1002\/gcc.20141","journal-title":"Genes Chromosomes Cancer"},{"key":"2922_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41467-017-00174-7","volume":"8","author":"S Agnihotri","year":"2017","unstructured":"Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K, Mansouri S, Karimi S, Sahm F, von Deimling A, Taylor MD, Laperriere NJ, Pugh TJ, Aldape KD, Zadeh G (2017) Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun 8:186. \n                    https:\/\/doi.org\/10.1038\/s41467-017-00174-7","journal-title":"Nat Commun"},{"key":"2922_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/sj.emboj.7600136","volume":"23","author":"X Qian","year":"2004","unstructured":"Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. Embo J 23:1739\u20131748","journal-title":"Embo J"},{"key":"2922_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI (2007) Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin. J Cell Biol 177:893\u2013903","journal-title":"J Cell Biol"},{"key":"2922_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/MCB.01139-07","volume":"28","author":"BK Cole","year":"2008","unstructured":"Cole BK, Curto M, Chan AW, McClatchey AI (2008) Localization to the cortical cytoskeleton is necessary for Nf2\/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol 28:1274\u20131284. \n                    https:\/\/doi.org\/10.1128\/MCB.01139-07","journal-title":"Mol Cell Biol"},{"key":"2922_CR21","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA (2010) ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology 12:834\u2013843. \n                    https:\/\/doi.org\/10.1093\/neuonc\/noq012","journal-title":"Neuro-Oncology"},{"key":"2922_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, Hochman T, Goldberg JD, Koch KM, Golfinos JG, Roland JT, Allen JC (2012) Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology 14:1163\u20131170. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nos146","journal-title":"Neuro-Oncology"},{"key":"2922_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","volume":"93","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Halpin C, Blakeley JO, Slattery WH 3rd, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG 2nd (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neuro-Oncol 93:61\u201377. \n                    https:\/\/doi.org\/10.1007\/s11060-009-9867-7","journal-title":"J Neuro-Oncol"},{"key":"2922_CR24","doi-asserted-by":"publisher","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"FP Nunes","year":"2013","unstructured":"Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG 2nd, Stemmer-Rachamimov A, Plotkin SR (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8:e59941. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0059941","journal-title":"PLoS ONE"},{"key":"2922_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, Hochman T, Goldberg JD, Vega E, Wisoff JH, Golfinos JG, Merkelson A, Roland JT, Allen JC (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology 16:292\u2013297. \n                    https:\/\/doi.org\/10.1093\/neuonc\/not150","journal-title":"Neuro-Oncology"},{"key":"2922_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neuro-Oncol 122:313\u2013320. \n                    https:\/\/doi.org\/10.1007\/s11060-014-1710-0","journal-title":"J Neuro-Oncol"},{"key":"2922_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","volume":"96","author":"AD Norden","year":"2010","unstructured":"Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neuro-Oncol 96:211\u2013217. \n                    https:\/\/doi.org\/10.1007\/s11060-009-9948-7","journal-title":"J Neuro-Oncol"},{"key":"2922_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","volume":"2","author":"I Vivanco","year":"2012","unstructured":"Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK (2012) Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458\u2013471. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0284","journal-title":"Cancer Discov"},{"key":"2922_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-013-1166-7","volume":"114","author":"M Fouladi","year":"2013","unstructured":"Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Goldman S, Geyer JR, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2013) A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neuro-Oncol 114:173\u2013179. \n                    https:\/\/doi.org\/10.1007\/s11060-013-1166-7","journal-title":"J Neuro-Oncol"},{"key":"2922_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"M Karajannis","year":"2012","unstructured":"Karajannis M, Bergner A, Giovannini M, Welling DB, Niparko J, Slattery W, Roland JT, Golfinos J, Allen J, Blakeley J (2012) Intratumoral concentration and molecular pharmacodynamics of lapatinib in vivo in sporadic and Nf2-related vestibular schwannomas. Neuro-Oncology 14:19\u201319","journal-title":"Neuro-Oncology"},{"key":"2922_CR31","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","volume":"13","author":"C Grommes","year":"2011","unstructured":"Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB (2011) \u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology 13:1364\u20131369. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nor121","journal-title":"Neuro-Oncology"},{"key":"2922_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10549-016-3798-8","volume":"157","author":"P Lavaud","year":"2016","unstructured":"Lavaud P, Rousseau B, Ajgal Z, Arrondeau J, Huillard O, Alexandre J, Hulin A, Goldwasser F (2016) Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis. Breast Cancer Res Treat 157:191\u2013192. \n                    https:\/\/doi.org\/10.1007\/s10549-016-3798-8","journal-title":"Breast Cancer Res Treat"},{"key":"2922_CR33","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1158\/1078-0432.CCR-09-0522","volume":"15","author":"AJ Chien","year":"2009","unstructured":"Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM (2009) A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin Cancer Res 15:5569\u20135575. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0522","journal-title":"Clin Cancer Res"},{"key":"2922_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2533-6","author":"A Yu","year":"2017","unstructured":"Yu A, Faiq N, Green S, Lai A, Green R, Hu J, Cloughesy TF, Mellinghoff I, Nghiemphu PL (2017) Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. J Neuro-Oncol. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2533-6","journal-title":"J Neuro-Oncol"},{"key":"2922_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285\u2013289. \n                    https:\/\/doi.org\/10.1038\/ng.2526","journal-title":"Nat Genet"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2922-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:31:11Z","timestamp":1589700671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2922-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2922-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"22 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}